Scarica l'app Stockscreener
265.79
0.48%
1.27
Dopo l'orario di chiusura:
265.32
-0.47
-0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie (NYSE:ABBV) Large-Cap Healthcare Strategy Gains Attention - Kalkine Media
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market - Trefis
AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026 - Yahoo Finance
AbbVie Presents New Data Across Lung Cancer Pipeline At WCLC 2026 - marketscreener.com
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - Investing News Network
AbbVie presents lung cancer data at WCLC 2026 conference By Investing.com - Investing.com Canada
AbbVie will present 90% lung cancer response data; the treatment remains investigational - Stock Titan
AbbVie Stock's Uncoupled Performance - Trefis
Jennison Associates LLC Trims Stake in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Acquires 5,934 Shares of AbbVie Inc. $ABBV - MarketBeat
Hodges Capital Management Inc. Has $4.94 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead - AOL.com
Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie stock hits fresh 52-week high as earnings strength and guidance lift outlook - Ad-hoc-news.de
AbbVie Inc. $ABBV Shares Sold by D.A. Davidson & CO. - MarketBeat
Benjamin Edwards Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability - TradingView
GUBRA: Revenue fell after last year's AbbVie deal, but clinical and CRO progress support long-term growth - TradingView
AbbVie (ABBV) Earnings Report: EPS Does Not Reach the Reported Estimate in the Current Update; Stock Move: The Stock Gains 2.72%Cost Structure Review - Vinanet
AbbVie Raises $9 Billion Debt to Fund Acquisition - The Globe and Mail
AbbVie (NYSE:ABBV) Shares Up 2.6%What's Next? - MarketBeat
Is AbbVie Stock About To Break Out Again? - Yahoo Finance
HARMONY ASSET MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Billionaire Ken Griffin Increased His Position in This Dividend King by 547% - Yahoo Finance
Munich Reinsurance Co Stock Corp in Munich Has $39.59 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 32,710 Shares - MarketBeat
AbbVie stock holds firm after Q2 revenue beat - Ad-hoc-news.de
Is AbbVie Inc (ABBV) Overvalued After 3.4% Rally? GF Value Says - GuruFocus
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
AbbVie (NYSE:ABBV) Trading Up 3.5%Still a Buy? - MarketBeat
Form 8K AbbVie Inc For: 18 August By Investing.com - Investing.com Nigeria
AbbVie completes $8.75B note offering to fund Apogee acquisition - TradingView
AbbVie (NYSE: ABBV) issues new senior notes with Apogee-linked redemption - Stock Titan
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled - TradingKey
Revance hires Janelle Wichmann as chief marketing officer of skincare unit - Fierce Pharma
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support - Investing News Network
AbbVie Inc. $ABBV Shares Sold by Capital Investment Advisory Services LLC - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by ABN Amro Investment Solutions - MarketBeat
Abundance Wealth Counselors Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Wells Fargo raises Abbvie stock price target on HS drug potential - Investing.com Canada
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? - AOL.com
Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating - marketscreener.com
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth With A 10.74% Potential Upside - DirectorsTalk Interviews
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? - AOL.com
AbbVie Inc. $ABBV Shares Bought by Exchange Traded Concepts LLC - MarketBeat
Bellecapital International Ltd. Acquires 8,728 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Confluence Wealth Services Inc. - MarketBeat
Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year - AOL.com
RWQ Financial Management Services Inc. Acquires 31,510 Shares of AbbVie Inc. $ABBV - MarketBeat
Mirae Asset Global Investments Co. Ltd. Has $124.56 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Synergy Asset Management LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
Campbell Newman Asset Management Inc. Sells 10,481 Shares of AbbVie Inc. $ABBV - MarketBeat
VIP Health Care Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
ABBV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbbVie (ABBV) Stock May Trade At A Premium Despite Cash Flow Upside - Yahoo Finance
SOA Wealth Advisors LLC. Sells 13,215 Shares of AbbVie Inc. $ABBV - MarketBeat
RWQ Financial Management Services, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. $ABBV Stake Boosted by Envestnet Portfolio Solutions Inc. - MarketBeat
Kepler Cheuvreux (Suisse) SA's AbbVie Inc(ABBV) Holding History - GuruFocus
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
AbbVie Defends Its Turf, But Leaves One Big Question Open - Trefis
AbbVie Inc. SEC Filing (Aug 14, 2026) - Stock Titan
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026? - Yahoo Finance
3.84%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):